山东鲁抗医药股份有限公司关于公司及控股子公司参与第十一批全国药品集中采购中选的公告

Group 1 - The company and its subsidiary, Shandong Lukang Pharmaceutical Group Sait Company, have been selected for the 11th batch of national drug centralized procurement [1][2] - The selected products are expected to generate a total sales revenue of 404.76 million yuan in 2024, accounting for approximately 6.49% of the company's total revenue for that year [1] - For the first half of 2025, the selected products are projected to yield sales of 225.24 million yuan, representing about 7.14% of the company's revenue for that period [1] Group 2 - The centralized procurement aims to prioritize the use of selected products in national medical institutions, facilitating quicker market entry for new products and expanding the company's coverage in relevant drug sectors [2] - The profitability of the selected products may face temporary adjustments, but the company plans to enhance operational management quality through product structure optimization and cost control measures [2]